Cargando…

MDM2-P53 Signaling Pathway-Mediated Upregulation of CDC20 Promotes Progression of Human Diffuse Large B-Cell Lymphoma

BACKGROUND: Cell-division cycle 20 (CDC20) is overexpressed in a variety of tumor cells and is negatively regulated by wild-type p53 (wtp53). Our previous study uncovered that CDC20 was upregulated and associated with poor outcome in diffuse large B-cell lymphoma (DLBCL) based on bioinformatics anal...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Chengtao, Li, Mengzhen, Feng, Yanfen, Sun, Feifei, Zhang, Li, Xu, Yanjie, Lu, Suying, Zhu, Jia, Huang, Junting, Wang, Juan, Hu, Yang, Zhang, Yizhuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7575066/
https://www.ncbi.nlm.nih.gov/pubmed/33116627
http://dx.doi.org/10.2147/OTT.S253758
_version_ 1783597742028750848
author Sun, Chengtao
Li, Mengzhen
Feng, Yanfen
Sun, Feifei
Zhang, Li
Xu, Yanjie
Lu, Suying
Zhu, Jia
Huang, Junting
Wang, Juan
Hu, Yang
Zhang, Yizhuo
author_facet Sun, Chengtao
Li, Mengzhen
Feng, Yanfen
Sun, Feifei
Zhang, Li
Xu, Yanjie
Lu, Suying
Zhu, Jia
Huang, Junting
Wang, Juan
Hu, Yang
Zhang, Yizhuo
author_sort Sun, Chengtao
collection PubMed
description BACKGROUND: Cell-division cycle 20 (CDC20) is overexpressed in a variety of tumor cells and is negatively regulated by wild-type p53 (wtp53). Our previous study uncovered that CDC20 was upregulated and associated with poor outcome in diffuse large B-cell lymphoma (DLBCL) based on bioinformatics analysis. Dysregulation of the MDM2-p53 is a major mechanism to promote DLBCL. Thus, we hypothesized that CDC20 could be a downstream gene of the MDM2-p53 signaling pathway. However, the clinical significance and mechanistic role of a novel MDM2-p53-CDC20 signaling pathway in DLBCL have still remained unclear. MATERIALS AND METHODS: RT-qPCR was performed in MDM2 knocked down (KD) and control (Ctrl) OCI-Ly3/OCI-Ly10 cells to investigate whether CDC20 was a downstream gene of the MDM2-p53 pathway. The effects of CDC20 on cell proliferation, cell cycle and apoptosis were assessed, as well as the role of CDC20 in suppressing tumorigenicity in vivo. Furthermore, we also investigated the roles of CDC20 and MDM2 in progression of DLBCL and the underlying mechanisms. RESULTS: The results of RT-qPCR revealed that CDC20 was downregulated while TP53 was upregulated in MDM2 KD OCI-Ly3 and OCI-Ly10 cells. It was unveiled that the expression levels of CDC20 and MDM2 were upregulated in DLBCL tissues and cells, and high CDC20 expression was correlated with adverse clinical features and poor outcome. Functional assays showed that downregulation of CDC20 could inhibit proliferation, induce apoptosis and cell cycle arrest in vitro. In addition, inactivation of the MDM2-p53 pathway by downregulation of MDM2 restored wtp53 expression level and reduced CDC20 protein level in OCI-Ly3 and OCI-Ly10 cells. Besides, targeting CDC20 was found to suppress tumorigenesis of DLBCL in vivo. CONCLUSION: CDC20 was identified as a key downstream gene of the MDM2-p53 signaling pathway in DLBCL and may be used as a novel target gene to guide therapeutic applications.
format Online
Article
Text
id pubmed-7575066
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-75750662020-10-27 MDM2-P53 Signaling Pathway-Mediated Upregulation of CDC20 Promotes Progression of Human Diffuse Large B-Cell Lymphoma Sun, Chengtao Li, Mengzhen Feng, Yanfen Sun, Feifei Zhang, Li Xu, Yanjie Lu, Suying Zhu, Jia Huang, Junting Wang, Juan Hu, Yang Zhang, Yizhuo Onco Targets Ther Original Research BACKGROUND: Cell-division cycle 20 (CDC20) is overexpressed in a variety of tumor cells and is negatively regulated by wild-type p53 (wtp53). Our previous study uncovered that CDC20 was upregulated and associated with poor outcome in diffuse large B-cell lymphoma (DLBCL) based on bioinformatics analysis. Dysregulation of the MDM2-p53 is a major mechanism to promote DLBCL. Thus, we hypothesized that CDC20 could be a downstream gene of the MDM2-p53 signaling pathway. However, the clinical significance and mechanistic role of a novel MDM2-p53-CDC20 signaling pathway in DLBCL have still remained unclear. MATERIALS AND METHODS: RT-qPCR was performed in MDM2 knocked down (KD) and control (Ctrl) OCI-Ly3/OCI-Ly10 cells to investigate whether CDC20 was a downstream gene of the MDM2-p53 pathway. The effects of CDC20 on cell proliferation, cell cycle and apoptosis were assessed, as well as the role of CDC20 in suppressing tumorigenicity in vivo. Furthermore, we also investigated the roles of CDC20 and MDM2 in progression of DLBCL and the underlying mechanisms. RESULTS: The results of RT-qPCR revealed that CDC20 was downregulated while TP53 was upregulated in MDM2 KD OCI-Ly3 and OCI-Ly10 cells. It was unveiled that the expression levels of CDC20 and MDM2 were upregulated in DLBCL tissues and cells, and high CDC20 expression was correlated with adverse clinical features and poor outcome. Functional assays showed that downregulation of CDC20 could inhibit proliferation, induce apoptosis and cell cycle arrest in vitro. In addition, inactivation of the MDM2-p53 pathway by downregulation of MDM2 restored wtp53 expression level and reduced CDC20 protein level in OCI-Ly3 and OCI-Ly10 cells. Besides, targeting CDC20 was found to suppress tumorigenesis of DLBCL in vivo. CONCLUSION: CDC20 was identified as a key downstream gene of the MDM2-p53 signaling pathway in DLBCL and may be used as a novel target gene to guide therapeutic applications. Dove 2020-10-15 /pmc/articles/PMC7575066/ /pubmed/33116627 http://dx.doi.org/10.2147/OTT.S253758 Text en © 2020 Sun et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Sun, Chengtao
Li, Mengzhen
Feng, Yanfen
Sun, Feifei
Zhang, Li
Xu, Yanjie
Lu, Suying
Zhu, Jia
Huang, Junting
Wang, Juan
Hu, Yang
Zhang, Yizhuo
MDM2-P53 Signaling Pathway-Mediated Upregulation of CDC20 Promotes Progression of Human Diffuse Large B-Cell Lymphoma
title MDM2-P53 Signaling Pathway-Mediated Upregulation of CDC20 Promotes Progression of Human Diffuse Large B-Cell Lymphoma
title_full MDM2-P53 Signaling Pathway-Mediated Upregulation of CDC20 Promotes Progression of Human Diffuse Large B-Cell Lymphoma
title_fullStr MDM2-P53 Signaling Pathway-Mediated Upregulation of CDC20 Promotes Progression of Human Diffuse Large B-Cell Lymphoma
title_full_unstemmed MDM2-P53 Signaling Pathway-Mediated Upregulation of CDC20 Promotes Progression of Human Diffuse Large B-Cell Lymphoma
title_short MDM2-P53 Signaling Pathway-Mediated Upregulation of CDC20 Promotes Progression of Human Diffuse Large B-Cell Lymphoma
title_sort mdm2-p53 signaling pathway-mediated upregulation of cdc20 promotes progression of human diffuse large b-cell lymphoma
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7575066/
https://www.ncbi.nlm.nih.gov/pubmed/33116627
http://dx.doi.org/10.2147/OTT.S253758
work_keys_str_mv AT sunchengtao mdm2p53signalingpathwaymediatedupregulationofcdc20promotesprogressionofhumandiffuselargebcelllymphoma
AT limengzhen mdm2p53signalingpathwaymediatedupregulationofcdc20promotesprogressionofhumandiffuselargebcelllymphoma
AT fengyanfen mdm2p53signalingpathwaymediatedupregulationofcdc20promotesprogressionofhumandiffuselargebcelllymphoma
AT sunfeifei mdm2p53signalingpathwaymediatedupregulationofcdc20promotesprogressionofhumandiffuselargebcelllymphoma
AT zhangli mdm2p53signalingpathwaymediatedupregulationofcdc20promotesprogressionofhumandiffuselargebcelllymphoma
AT xuyanjie mdm2p53signalingpathwaymediatedupregulationofcdc20promotesprogressionofhumandiffuselargebcelllymphoma
AT lusuying mdm2p53signalingpathwaymediatedupregulationofcdc20promotesprogressionofhumandiffuselargebcelllymphoma
AT zhujia mdm2p53signalingpathwaymediatedupregulationofcdc20promotesprogressionofhumandiffuselargebcelllymphoma
AT huangjunting mdm2p53signalingpathwaymediatedupregulationofcdc20promotesprogressionofhumandiffuselargebcelllymphoma
AT wangjuan mdm2p53signalingpathwaymediatedupregulationofcdc20promotesprogressionofhumandiffuselargebcelllymphoma
AT huyang mdm2p53signalingpathwaymediatedupregulationofcdc20promotesprogressionofhumandiffuselargebcelllymphoma
AT zhangyizhuo mdm2p53signalingpathwaymediatedupregulationofcdc20promotesprogressionofhumandiffuselargebcelllymphoma